Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Generating novel MYOD1 L122R murine models and characterizing the immune microenvironment of rhabdomyosarcoma

FY 2024-25

Summary
Rhabdomyosarcoma (RMS) is a muscle cancer that most often occurs in children. Patients with recurrent/relapsed RMS have poor outcomes and systemic toxicity due to chemotherapy treatment. Recently, a subset of patients with a specific mutation in the MYOD1 gene have been identified to have even poorer outcomes than their counterparts. This demonstrates a need for more effective and less systemically toxic therapies. Our research aims to accomplish this by creating/using models of disease for which we can test immunotherapies (treatments aimed at harnessing the immune system to kill cancer) as well as other combination therapies. Previously, we combined thermosensitive liposomal doxorubicin - a drug that releases chemotherapy only when heated, with non-invasive localized heating of tumours in our mouse model of RMS to target heat release of the drug at the site of the tumour. This treatment increased survival and decreased off-target chemotherapy accumulation. Because heat can stimulate the immune system, we want to know whether we can harness the heat from this already promising treatment and combine it with immunotherapy to create an even more effective treatment strategy. To do this we will characterize immune cell populations and their relationships in this model and the different heat treatment groups to identify promising immune checkpoint markers and their corresponding immunotherapeutic drugs with/without heat. To do the same with patients that have a MYOD1 mutation, we are working in tandem to create an immune-competent mouse model of RMS that overexpresses this specific mutation using virus transduction. This research will improve patient outcomes by identifying novel therapies that can then be translated to clinical trials and implemented in children with cancer to increase patient survival and decrease systemic toxicity. Moreover, these models will establish a foundation for immunotherapy testing in RMS which can be used indefinitely in future research.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
518370
Name
Nomikos Julia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Generating novel MYOD1 L122R murine models and characterizing the immune microenvironment of rhabdomyosarcoma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Hyperthermia; Immune Microenvironment; Magnetic Resonance Guided High Intensity Focused Ultrasound; Myod1 L122r; Rhabdomyosarcoma; Syngeneic Mouse Models; Thermosensitive Liposomal Doxorubicin
Abstract
Rhabdomyosarcoma (RMS) is a muscle cancer that most often occurs in children. Patients with recurrent/relapsed RMS have poor outcomes and systemic toxicity due to chemotherapy treatment. Recently, a subset of patients with a specific mutation in the MYOD1 gene have been identified to have even poorer outcomes than their counterparts. This demonstrates a need for more effective and less systemically toxic therapies. Our research aims to accomplish this by creating/using models of disease for which we can test immunotherapies (treatments aimed at harnessing the immune system to kill cancer) as well as other combination therapies. Previously, we combined thermosensitive liposomal doxorubicin - a drug that releases chemotherapy only when heated, with non-invasive localized heating of tumours in our mouse model of RMS to target heat release of the drug at the site of the tumour. This treatment increased survival and decreased off-target chemotherapy accumulation. Because heat can stimulate the immune system, we want to know whether we can harness the heat from this already promising treatment and combine it with immunotherapy to create an even more effective treatment strategy. To do this we will characterize immune cell populations and their relationships in this model and the different heat treatment groups to identify promising immune checkpoint markers and their corresponding immunotherapeutic drugs with/without heat. To do the same with patients that have a MYOD1 mutation, we are working in tandem to create an immune-competent mouse model of RMS that overexpresses this specific mutation using virus transduction. This research will improve patient outcomes by identifying novel therapies that can then be translated to clinical trials and implemented in children with cancer to increase patient survival and decrease systemic toxicity. Moreover, these models will establish a foundation for immunotherapy testing in RMS which can be used indefinitely in future research.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nomikos, Julia
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~